Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Thursday, Zacks reports.
Several other brokerages have also recently commented on BIOVF. Nordea Equity Research cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, October 22nd. Pareto Securities upgraded Swedish Orphan Biovitrum from a “hold” rating to a “buy” rating in a report on Tuesday, October 27th. Finally, HC Wainwright restated a “buy” rating on shares of Swedish Orphan Biovitrum in a report on Wednesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.
Read Our Latest Report on Swedish Orphan Biovitrum
Swedish Orphan Biovitrum Stock Performance
Shares of Swedish Orphan Biovitrum stock opened at $51.05 on Thursday. The stock’s fifty day simple moving average is $46.40 and its 200 day simple moving average is $45.13. The company has a current ratio of 0.88, a quick ratio of 0.55 and a debt-to-equity ratio of 0.20. The company has a market capitalization of $18.17 billion, a PE ratio of 23.42 and a beta of 0.48. Swedish Orphan Biovitrum has a 12 month low of $35.25 and a 12 month high of $51.05.
Swedish Orphan Biovitrum Company Profile
Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.
Recommended Stories
- Five stocks we like better than Swedish Orphan Biovitrum
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.
